A 2:1 Inhaled CBD–THC Ratio Did Not Prevent Memory Effects
Twice as much CBD as THC did not eliminate THC-related memory effects in a randomized inhalation study. The findings also varied by symptom scale, making a general claim of either complete protection or a uniform psychotic response inaccurate.
Four conditions in the same participants
Forty-eight cannabis users completed a blinded crossover comparison of placebo, 8 mg THC, 16 mg CBD, and the combination. Cannabinoids were delivered by vaporizer. Participants were selected across cannabis-use frequency and schizotypal-trait groups.
This human experiment tested concurrent inhalation. It should not be treated as the same exposure as giving a large oral CBD dose hours before THC, or as a trial of CBD treatment in patients with diagnosed schizophrenia.
Memory and symptom scales did not behave identically
THC alone and THC with CBD impaired episodic and working-memory performance. Both also increased selected psychotomimetic outcomes, including perceptual distortion and cognitive disorganization. CBD did not offset these effects at the tested ratio.
However, group-level paranoia and positive-symptom ratings did not show the same increases. CBD alone reduced overall psychotomimetic ratings in lighter users, rather than demonstrating a uniform benefit across all participants. Naming the actual domain avoids turning one significant scale into a claim about every symptom.
The ratio is only part of the exposure
The experiment does not establish how another dose, sequence, route or cannabis product would behave. Selection of existing cannabis users and possible tolerance also restrict generalization to people with little previous exposure.
A symptom-scale change is not a diagnosis of a persistent psychiatric disorder, and a memory-task effect is not a measured crash outcome. The evidence directly challenges a blanket claim that a 2:1 CBD–THC ratio necessarily neutralizes THC, while leaving other combinations and clinical questions unresolved.
Related: Why cannabinoid concentration and impairment require separate interpretation.
Primary research
Individual and combined effects of acute delta-9-tetrahydrocannabinol and cannabidiol on psychotomimetic symptoms and memory function. Translational Psychiatry (2018).
